REPLIMUNE GROUP, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
REPLIMUNE GROUP, INC. (REPL) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of -4.90% for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-06-29
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2026 was -4.90%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was -1.60%, a 328.57% decline from fiscal 2024.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was 0.70%, a 30.00% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was 1.00%, a 0.00% change from fiscal 2022.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month as first filed |
|---|---|---|
| 2026-03-31 | -4.90% 10-K · filed 2026-06-29 | |
| 2025-03-31 | -1.60% 10-K · filed 2026-06-29 | |
| 2024-03-31 | 0.70% 10-K · filed 2025-05-22 | |
| 2023-03-31 | 1.00% 10-K · filed 2024-05-16 | |
| 2022-03-31 | 1.00% 10-K · filed 2023-05-18 | 0.00% 10-K · filed 2022-05-19 |
| 2021-03-31 | -0.80% 10-K · filed 2022-05-19 | 0.80% 10-K · filed 2021-05-20 |
| 2020-03-31 | 0.00% 10-K · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |